This is an aggregated industry headline. Read the full story at FierceBiotech →
At first public hearing for FDA's CNPV program, industry support meets 'deep concern' from experts
On Thursday, the public had the first chance to air their grievances about the FDA's controversial Commissioner's National Priority Voucher (CNPV) pilot program, the flagship initiative of recently departed agency leader Marty Makary, M.D.
By FierceBiotech
· Jun 5, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufac…
The WeekFierceBiotech ↗
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last …
The WeekBriefing
CMS and state actions under the American Rescue Plan Act and later legislation have made yearlong postpartum c…